Ischemic mitral regurgitation is extremely difficult to manage. That’s why Dr. Deborah Kwon is intent on identifying imaging-based predictors of progression to enable earlier and wiser intervention.
Despite their popularity, wrist-worn fitness trackers aren’t reliable for accurately monitoring heart rate, and accuracy varies among leading models. So reports one of the first-ever studies of the devices.
In healthy patients undergoing EGD or colonoscopy with moderate sedation, capnography increases costs without adding safety benefit, first-of-its-kind study shows
Beyond revealing the value of surgery for many patients with BAV, a new cohort analysis shows why Cleveland Clinic now routinely performs CT or MRI in these patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
One of Cleveland Clinic’s advanced practice nurses has conducted seminal research on delirium screening and early progressive mobility in the neurological ICU. Find out why she’s so passionate about nursing research.
Educating heart failure patients is important to managing lifestyle after hospital discharge. But are nurses comfortable providing self-care education? A published study by a Cleveland Clinic ACNO reveals telling results.
In the first longitudinal study to compare brain activity and cognitive function in cognitively intact elders with and without a key gene marker for Alzheimer disease, fMRI demonstrated clear differences.
The largest analyses to date of autism in twins and in females have yielded some novel insights. Lead researcher Thomas Frazier, PhD, gives the lowdown, and looks ahead to a Rett syndrome trial.
Adult ICU patients are at risk for fecal incontinence that can result in pressure ulcers and anal erosion. Nurse researchers at Cleveland Clinic studied the effect of fecal management systems on the incidence of anal erosion.
With more than half a million dollars in funding secured, a Cleveland Clinic team is embarking on the process of developing and testing a new Alzheimer’s drug, MDA7, a cannabinoid type 2 receptor-selective agonist.